NCT/Study#
NCT03625037 /
GCT3013-01
A Phase 1/2, Open-Label, Dose-Escalation Trial Of GEN3013 In Patients With Relapsed, Progressive Or Refractory B-Cell Lymphoma
DISEASE GROUP:
Lymphoma
current phase:
Phase I/II
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information:
Call 201-518-3587
